TY - JOUR
T1 - Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments
T2 - Safety, Efficacy, Limitations and Challenges
AU - Gomez-Escolar, Anton
AU - Folch-Sanchez, Daniel
AU - Stefaniuk, Joanna
AU - Swithenbank, Zoe
AU - Nisa, Andreia
AU - Braddick, Fleur
AU - Idrees Chaudhary, Nazish
AU - van der Meer, Pim B
AU - Batalla, Albert
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024.
PY - 2024/10
Y1 - 2024/10
N2 - Mental health disorders and substance use disorders (SUDs) in particular, contribute greatly to the global burden of disease. Psychedelics, including entactogens and dissociative substances, are currently being explored for the treatment of SUDs, yet with less empirical clinical evidence than for other mental health disorders, such as depression or post-traumatic stress disorder (PTSD). In this narrative review, we discuss the current clinical research evidence, therapeutic potential and safety of psilocybin, lysergic acid diethylamide (LSD), ketamine, 3,4-methylenedioxymethamphetamine (MDMA) and ibogaine, particularly in the context of the SUD treatment. Our aim was to provide a balanced overview of the current research and findings on potential benefits and harms of psychedelics in clinical settings for SUD treatment. We highlight the need for more clinical research in this particular treatment area and point out some limitations and challenges to be addressed in future research.
AB - Mental health disorders and substance use disorders (SUDs) in particular, contribute greatly to the global burden of disease. Psychedelics, including entactogens and dissociative substances, are currently being explored for the treatment of SUDs, yet with less empirical clinical evidence than for other mental health disorders, such as depression or post-traumatic stress disorder (PTSD). In this narrative review, we discuss the current clinical research evidence, therapeutic potential and safety of psilocybin, lysergic acid diethylamide (LSD), ketamine, 3,4-methylenedioxymethamphetamine (MDMA) and ibogaine, particularly in the context of the SUD treatment. Our aim was to provide a balanced overview of the current research and findings on potential benefits and harms of psychedelics in clinical settings for SUD treatment. We highlight the need for more clinical research in this particular treatment area and point out some limitations and challenges to be addressed in future research.
UR - http://www.scopus.com/inward/record.url?scp=85199086198&partnerID=8YFLogxK
U2 - 10.1007/s40263-024-01101-3
DO - 10.1007/s40263-024-01101-3
M3 - Review article
C2 - 39033264
SN - 1172-7047
VL - 38
SP - 771
EP - 789
JO - CNS Drugs
JF - CNS Drugs
IS - 10
ER -